WILMINGTON, Mass., May 31, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2012 Global Healthcare Conference in New York City. The conference is being held at the Grand Hyatt Hotel, June 4-7, 2012. Mr. Doman is scheduled to present at 2:30 p.m. EDT on June 7, 2012. To access the live webcast of the presentation, interested parties can click here or visit our website at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website shortly following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform. Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using DUSA's BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.